Hwail Pharm Executive Kang Seong-yong's Shares Reduced to 907 via Stock Split; No Shareholder Value Impact

Kang Seong-yong, a non-registered executive of Hwail Pharm, reported a reduction of 8,171 shares from 9,078 to 907 due to a stock split on April 9, 2026.
This change is a simple adjustment from the stock split, not a sale, and his ownership ratio remains unchanged at 0.01%, thus no impact on existing shareholder value.
A stock split reduces the number of shares but proportionally increases the per-share value, leaving total equity value unchanged.
[AI Summary]The executive's share reduction from the stock split is a routine capital structure adjustment with no dilution or capital change, making it a neutral event for investors.